Neuland Laboratories (524558) Q4 24/25 earnings summary

Executive summary

• Q4 FY25 total income was INR 335.8 crores, down 14% year-over-year, with Prime and Specialty segments as main contributors.

• FY25 total income was INR 1,497.3 crores, a 4.7% decline from FY24.

• EBITDA for FY25 was INR 342.8 crores, a 27.8% decline year-over-year; Q4 FY25 EBITDA was INR 58.2 crores (17.3% margin).

• Profit after tax for FY25 was INR 259.4 crores, down 13.4% year-over-year; Q4 FY25 PAT was INR 27.7 crores; EPS at INR 202.2 for FY25 and INR 21.6 for Q4.

• Free cash flow for FY25 was INR 111 crores.

Financial highlights

• Gross margin for Q4 FY25 was 56.3%, down from 58.8% in Q4 FY24.

• Working capital stood at 107 days of sales at March-end.

• Net debt position improved to negative INR 228.7 crores at FY25 end after repaying INR 39.4 crores of term loan debt.

• CapEx investment of INR 206.4 crores in FY25; major CapEx of INR 350 crores approved for large-scale peptide manufacturing.

• Exceptional profit of INR 76.4 crores from investment property included in FY25 results.

Outlook and guidance

• Management expects growth to resume in FY26, referencing FY24 as the base due to FY25's degrowth.

• Both CMS and GDS segments are expected to grow in FY26, with CMS anticipated to recover more strongly.

• Commercial production from the new Unit 3 block is expected to start in FY26, supporting revenue momentum.

• Continued investments in peptides and CMS segments are expected to drive future growth.

• No quantitative guidance provided, but optimism expressed for margin improvement and long-term growth.